Physician profile
Robert E Jackson
NPI 1710965637
$3,622.29
in general payments reported to CMS, 2019-2025
49 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $640 · 2021: $421 · 2022: $393 · 2023: $609 · 2024: $404 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.21 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.73 | 2019-2025 | |
| Lilly USA, LLC | $298.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $225.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $213.14 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.69 | 2019-2024 | Jardiance |
| Amgen INC. | $158.61 | 2019-2023 | Otezla, Repatha, Evenity |
| Amarin Pharma, INC. | $148.67 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.64 | 2019-2025 | Trintellix |
| Novo Nordisk INC | $137.00 | 2019-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.06 | 2020-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $124.43 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Exact Sciences Corporation | $103.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $101.03 | 2020-2023 | |
| Astellas Pharma US INC | $98.23 | 2019-2025 | Veozah |
| Allergan, INC. | $88.32 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.